

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	42255
First Inventor	McCormick
Title	Self Antigen Vaccines for Treating B Cell Lymphomas and Other Cancers
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☒ Applicant claims small entity status.
See 37 CFR 1.27.
- ☒ Specification [Total Pages 85]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 5]
- ☒ Oath or Declaration [Total Pages]
 - ☐ Newly executed (original or copy)
 - ☒ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
- ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☐ Computer Readable Form (CRF)
 - Specification Sequence Listing on:
 - ☐ CD-ROM or CD-R (2 copies); or
 - ☒ paper
 - ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
- ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP)

Prior application information

Examiner G. Bansal

of prior application No. 09 / 522.900

Group Art Unit 1642

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

001609

(Insert Customer No. or Attach bar code label here)

or

☒

Correspondence address below

Name	Roylance, Abrams, Berdo & Goodman, L.L.P.				
Address	1300 19th Street, N.W. Suite 600				
City	Washington	State	D.C.	Zip Code	20036
Country	USA	Telephone	(202) 659-9076	Fax	(202) 659-9344

Name (Print/Type)	Dean H. Nakamura	Registration No. (Attorney/Agent)	33,981
Signature		Date	8 February 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

jc821 U.S. PTO
10/06/893
02/08/02

FEE TRANSMITTAL FORM

Attorney Docket No.: **42255**

ASSISTANT COMMISSIONER OF PATENTS

BOX: PATENT APPLICATION

Washington, D.C. 20231

Transmitted herewith for filing is the patent application of

Inventors: **Allison McCormick, Daniel Tuse, Stephen Reinl, John Lindbo and Thomas Turpen**


For: Self Antigen Vaccines for Treating B Cell Lymphomas and Other Cancers

The filing fee for filing this patent application has been calculated as follows:

		(Col. 1)	(Col. 2)	SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
FOR:		NO. FILED	NO. EXTRA	RATE	FEE		RATE	FEE
BASIC FEE					\$370.00	OR		\$740.00
TOTAL	22	- 20=	2	2 x 9 =	\$18.00		x 18 =	\$
INDEP	2	- 3=	0	x 42 =	\$		x 84 =	\$
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS				+ 140 =	\$140.00		+ 280 =	\$
If the difference in Col. 1 is less than zero, enter "0" in Col. 2				TOTAL	\$528.00		TOTAL	\$

- ☒ Applicant claims small entity status. See 37 CFR 1.27.
- ☒ Checks in the amount of **\$528.00** to cover the above calculated filing fee are enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 18-2220. A duplicate copy of this sheet is attached.
- ☒ Any additional patent application filing fees under 37 CFR 1.16.
- ☒ Any additional patent application processing fees under 37 CFR 1.17.

Dated: 8 February 2002


Dean H. Nakamura
Attorney of Record
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076